ID: MRFR/Pharma/0115-HCR | February 2021 | Region: Global | 90 pages
Market Scenario
Gastrointestinal Drugs Market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 42,180 Million in 2018 and is projected to register a valuation of USD 59,300 Million by 2025, with a CAGR of 4.9% over the forecast period.
The increasing prevalence of gastrointestinal diseases and rising investments and funding in the field of life science research are likely to provide favorable conditions for the growth of the market during the forecast period.
Various other factors, such as the changing lifestyle and increasing number of geriatric individuals, are also expected to propel the growth of the market.
However, high raw material costs and growing presence of counterfeit drugs can hamper market growth over the forecast period.
Segmentation
The global gastrointestinal drugs market is segmented based on drug class, route of administration, application, distribution channel, and region.
The global market for gastrointestinal drugs, by drug class, is segmented into acid neutralizers, anti-inflammatory drugs, antidiarrheal and laxatives, antiemetic and antinauseants, biologics, and others.
Based on route of administration, the market is segmented into oral, parenteral, and rectal.
Based on Application, the market is segmented into inflammatory ulcerative colitis, irritable bowel syndrome, Crohn's disease, celiac disease, gastroenteritis, and others.
Distribution channels are segmented into retail pharmacies, online pharmacies, and hospital pharmacies.
In the current scope of the study, the segments mentioned above are covered into the four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The gastrointestinal drugs market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European gastrointestinal drugs market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The gastrointestinal drugs market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gastrointestinal drugs market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Global Gastrointestinal Drugs Market Share (%), by Region, 2018
Sources: MRFR Analysis
The Americas dominated the global market for gastrointestinal drugs owing to the increasing digestive disorders, increasing healthcare expenditure, and presence of well-established healthcare sector in the region. According to the report published by the US Department of Health & Human Services, more than 15.3 million Americas were affected by ulcer in 2017, which is around 6.2% of total adult population. In 2018, it was estimated that Europe stood second in the gastrointestinal drugs market. The increasing awareness about digestive diseases, increasing investments in the healthcare industry in the region, and growing demand for efficient treatment solutions for gastrointestinal disorders is expected to drive the growth of the market. Germany held the largest share of the market for gastrointestinal drugs in the region.
Asia-Pacific (APAC) is expected to witness the fastest growth in the gastrointestinal drugs market throughout the forecast period due to the rising geriatric population, presence of a large patient pool, and increasing government initiatives for the growth of the healthcare sector in the region. Countries in Asia-Pacific are adopting advanced treatment options, which in turn fuels the market growth in this region. Moreover, presence of developing countries, such as China, India, and Japan, is expected to drive the market growth in the region.
On the other hand, the Middle East & Africa is expected to hold the least share of the gastrointestinal drugs market due to the low economic development, especially in Africa.
Key Players
Some of the Key Players operating in the Global Gastrointestinal Drugs Market are Takeda Pharmaceuticals, Allergan Plc, Novo Nordisk A/S, AstraZeneca Plc, AbbVie Inc., Valeant Pharmaceuticals Inc., Johnson & Johnson, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., and Sanofi.
Market Segmentation
Global Gastrointestinal Drugs Market, by Drug Class
Global Gastrointestinal Drugs Market, by Route of Administration
Global Gastrointestinal Drugs Market, by Application
Global Gastrointestinal Drugs Market, by Distribution Channel
Intended Audience
Frequently Asked Questions (FAQ) :
Gastrointestinal drugs market valuation can touch USD 59,300 million by 2025.
Gastrointestinal drugs market is expected to exhibit a CAGR of 4.9% from 2019 to 2025.
Gastrointestinal drugs market is driven by the alarming cases of GI among the masses.
Presence of counterfeit drugs and high raw material costs can restrain the global gastrointestinal drugs market growth.
GlaxoSmithKline Plc., Janssen Biotech Inc., Johnson & Johnson, Valeant Pharmaceuticals Inc., Boehringer Ingelheim GmbH, Takeda Pharmaceuticals, Allergan Plc, Bayer AG, Sanofi, AstraZeneca Plc, Novo Nordisk A/S, and AbbVie Inc. are major players of the global gastrointestinal drugs market.
Table of Contents:
Chapter 1. Executive Summary
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Overview
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 R&D and Designing
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-Sales Review
Chapter 6. Global Gastrointestinal Drugs Market, by Drug Class
6.1 Overview
6.2 Acid Neutralizers
6.2.1 Antacids
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
6.2.2 H2 Antagonists
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
6.2.3 Proton Pump Inhibitors
6.3 Anti-Inflammatory Drugs
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
6.4 Antidiarrheal and Laxatives
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
6.5 Antiemetic and Antinauseants
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
6.6 Biologics
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
6.7 Others
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
Chapter 7. Global Gastrointestinal Drugs Market, by Route of Administration
7.1 Overview
7.2 Oral
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
7.3 Parenteral
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
7.4 Rectal
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
Chapter 8. Global Gastrointestinal Drugs Market, by Application
8.1 Overview
8.2 Inflammatory Ulcerative Colitis
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
8.3 Irritable Bowel Syndrome
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
8.4 Crohn's Disease
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
8.5 Celiac Disease
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
8.6 Gastroenteritis
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
8.7 Others
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
Chapter 9. Global Gastrointestinal Drugs Market, by Distribution Channel
9.1 Overview
9.2 Retail Pharmacies
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
9.3 Retail Pharmacies
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
9.4 Hospital Pharmacies
Market Estimates & Forecast, by Region, 2019–2025
Market Estimates & Forecast, by Country, 2019–2025
Chapter 10. Global Gastrointestinal Drugs Market, by Region
10.1 Overview
10.2 Americas
10.2.1 North America
10.2.1.1 US
10.2.1.2 Canada
10.2.2 Latin America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 UK
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia-Pacific
10.5 Middle East & Africa
10.5.1 Middle East
10.5.2 Africa
Chapter 11. Company Landscape
11.1 Overview
11.2 Competitive Analysis
Chapter 12. Company Profile
12.1 Takeda Pharmaceticals
12.1.1 Company Overview
12.1.2 Products/Services Offered
12.1.3 Financial Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.1.6 Key Strategies
12.2 Allergan Plc
12.2.1 Company Overview
12.2.2 Products/Services Offered
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.2.6 Key Strategies
12.3 Novo Nordisk A/S
12.3.1 Company Overview
12.3.2 Products/Services Offered
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.3.6 Key Strategies
12.4 AstraZeneca Plc
12.4.1 Company Overview
12.4.2 Products/Services Offered
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.4.6 Key Strategies
12.5 AbbVie Inc.
12.5.1 Company Overview
12.5.2 Products/Services Offered
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.5.6 Key Strategies
12.6 Valeant Pharmaceuticals Inc.
12.6.1 Company Overview
12.6.2 Products/Services Offered
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.6.6 Key Strategies
12.7 Johnson & Johnson
12.7.1 Overview
12.7.2 Products/Services Offered
12.7.3 Financial Overview
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.7.6 Key Strategies
12.8 Bayer AG
12.8.1 Overview
12.8.2 Products/Services Offered
12.8.3 Financial Overview
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.8.6 Key Strategies
12.9 Boehringer Ingelheim GmbH
12.9.1 Overview
12.9.2 Products/Services Offered
12.9.3 Financial Overview
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.9.6 Key Strategies
12.10 GlaxoSmithKline Plc.
12.10.1 Overview
12.10.2 Products/Services Offered
12.10.3 Financial Overview
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.10.6 Key Strategies
12.11 Janssen Biotech Inc.
12.11.1 Overview
12.11.2 Products/Services Offered
12.11.3 Financial Overview
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.11.6 Key Strategies
12.12 Sanofi
12.12.1 Overview
12.12.2 Products/Services Offered
12.12.3 Financial Overview
12.12.4 Key Developments
12.12.5 SWOT Analysis
12.12.6 Key Strategies
12.13 Others
Chapter 12 Appendix
12.1 References
12.2 Related Reports
LIST OF TABLES
Table 1 Global Gastrointestinal Drugs Market Synopsis, 2019–2025
Table 2 Global Gastrointestinal Drugs Market Estimates and Forecast, 2019–2025 (USD Million)
Table 3 Global Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)
Table 4 Global Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)
Table 5 Global Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)
Table 6 Global Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 7 Global Gastrointestinal Drugs Market, by Region, 2019–2025 (USD Million)
Table 8 Americas: Gastrointestinal Drugs Market, by Region, 2018 and 2025
Table 9 Americas: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)
Table 10 Americas: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)
Table 11 Americas: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)
Table 12 Americas: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 13 North America: Gastrointestinal Drugs Market, by Country, 2019–2025 (USD Million)
Table 14 North America: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)
Table 15 North America: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)
Table 16 North America: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)
Table 17 North America: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 18 US: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)
Table 19 US: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)
Table 20 US: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)
Table 21 US: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 22 Canada: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)
Table 23 Canada: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)
Table 24 Canada: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)
Table 25 Canada: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 26 Latin America: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)
Table 27 Latin America: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)
Table 28 Latin America: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)
Table 29 Latin America: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 30 Europe: Gastrointestinal Drugs Market, by Region, 2019–2025 (USD Million)
Table 31 Europe: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)
Table 32 Europe: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)
Table 33 Europe: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)
Table 34 Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 35 Western Europe: Gastrointestinal Drugs Market, by Country, 2019–2025 (USD Million)
Table 36 Western Europe: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)
Table 37 Western Europe: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)
Table 38 Western Europe: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)
Table 39 Western Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 40 Eastern Europe: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)
Table 41 Eastern Europe: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)
Table 42 Eastern Europe: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)
Table 43 Eastern Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 44 Asia-Pacific: Gastrointestinal Drugs Market, by Country, 2019–2025 (USD Million)
Table 45 Asia-Pacific: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)
Table 46 Asia-Pacific: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)
Table 47 Asia-Pacific: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)
Table 48 Asia-Pacific: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
Table 49 Middle East & Africa: Gastrointestinal Drugs Market, by Region, 2019–2025 (USD Million)
Table 50 Middle East & Africa: Gastrointestinal Drugs Market, by Drug Class, 2019–2025 (USD Million)
Table 51 Middle East & Africa: Gastrointestinal Drugs Market, by Route of Administration, 2019–2025 (USD Million)
Table 52 Middle East & Africa: Gastrointestinal Drugs Market, by Application, 2019–2025 (USD Million)
Table 53 Middle East & Africa: Gastrointestinal Drugs Market, by Distribution Channel, 2019–2025 (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Market Structure of the Global Gastrointestinal Drugs Market
Figure 3 Market Dynamics of the Global Gastrointestinal Drugs Market
Figure 4 Global Gastrointestinal Drugs Market Share, by Drug Class, 2018 (%)
Figure 5 Global Gastrointestinal Drugs Market Share, by Drug Class, 2018 (USD Million)
Figure 6 Global Gastrointestinal Drugs Market Share, by Route of Administration, 2018 (%)
Figure 7 Global Gastrointestinal Drugs Market Share, by Route of Administration, 2018 (USD Million)
Figure 8 Global Gastrointestinal Drugs Market Share, by Application, 2018 (%)
Figure 9 Global Gastrointestinal Drugs Market Share, by Application, 2018 (USD Million)
Figure 10 Global Gastrointestinal Drugs Market Share, by Distribution Channel, 2018 (%)
Figure 11 Global Gastrointestinal Drugs Market Share, by Distribution Channel, 2018 (USD Million)
Figure 12 Global Gastrointestinal Drugs Market Share, by Region, 2018 (%)
Figure 13 Americas: Gastrointestinal Drugs Market Share, by Region, 2018 (%)
Figure 14 North America: Gastrointestinal Drugs Market Share, by Country, 2018 (%)
Figure 15 Europe: Gastrointestinal Drugs Market Share, by Region, 2018 (%)
Figure 16 Western Europe: Gastrointestinal Drugs Market Share, by Country, 2018 (%)
Figure 17 Asia-Pacific: Gastrointestinal Drugs Market Share, by Country, 2018 (%)
Figure 18 Middle East & Africa: Gastrointestinal Drugs Market Share, by Region, 2018 (%)
Figure 19 Global Gastrointestinal Drugs Market: Company Share Analysis, 2018 (%)
Figure 20 Takeda Pharmaceuticals: Key Financials
Figure 21 Takeda Pharmaceuticals: Segmental Revenue
Figure 22 Taked a Pharmaceuticals: Regional Revenue
Figure 23 Allergan Plc: Key Financials
Figure 24 Allergan Plc: Segmental Revenue
Figure 25 Allergan Plc: Regional Revenue
Figure 26 Novo Nordisk A/S: Key Financials
Figure 27 Novo Nordisk A/S: Segmental Revenue
Figure 28 Novo Nordisk A/S: Regional Revenue
Figure 29 AstraZeneca Plc: Key Financials
Figure 30 AstraZeneca Plc: Segmental Revenue
Figure 31 AstraZeneca Plc: Regional Revenue
Figure 32 AbbVie Inc.: Key Financials
Figure 33 AbbVie Inc.: Segmental Revenue
Figure 34 AbbVie Inc.: Regional Revenue
Figure 35 Valeant Pharmaceuticals Inc.: Key Financials
Figure 36 Valeant Pharmaceuticals Inc.: Segmental Revenue
Figure 37 Valeant Pharmaceuticals Inc.: Regional Revenue
Figure 38 Johnson & Johnson: Key Financials
Figure 39 Johnson & Johnson: Segmental Revenue
Figure 40 Johnson & Johnson: Regional Revenue
Figure 41 Bayer AG: Key Financials
Figure 42 Bayer AG: Segmental Revenue
Figure 43 Bayer AG: Regional Revenue
Figure 44 Boehringer Ingelheim GmbH: Key Financials
Figure 45 Boehringer Ingelheim GmbH: Segmental Revenue
Figure 46 Boehringer Ingelheim GmbH: Regional Revenue
Figure 47 GlaxoSmithKline Plc.: Key Financials
Figure 48 GlaxoSmithKline Plc.: Segmental Revenue
Figure 49 GlaxoSmithKline Plc.: Regional Revenue
Figure 50 Janssen Biotech Inc.: Key Financials
Figure 51 Janssen Biotech Inc.: Segmental Revenue
Figure 52 Janssen Biotech Inc.: Regional Revenue
Figure 53 Sanofi: Key Financials
Figure 54 Sanofi: Segmental Revenue
Figure 55 Sanofi: Regional Revenue